Drug interactions
Amivantamab + Lazertinib
Severity: Moderate
Amivantamab and Lazertinib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Amivantamab with lazertinib raises the risk of venous thromboembolism, and prophylaxis is recommended. Vitamin K antagonists are poorly suited for this because their variable effect makes control difficult, whereas the interaction concerns the combination's thrombotic risk.
What this interaction means in plain words
Amivantamab and Lazertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Amivantamab belongs to Oncology; Lazertinib belongs to Oncology.
Why it happens
The combination increases thromboembolic risk by an incompletely established mechanism.
What to do
Give anticoagulant prophylaxis during the first months of therapy, preferably with a direct oral anticoagulant or low molecular weight heparin rather than a vitamin K antagonist. Monitor for signs of VTE.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Amivantamab and Lazertinib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 14 days on the web. No card needed.
Frequently asked questions
Can I take Amivantamab with Lazertinib?
MediHelp rates the interaction as moderate. Amivantamab and Lazertinib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Amivantamab with lazertinib raises the risk of venous thromboembolism, and prophylaxis is recommended. Vitamin K antagonists are poorly suited for this because their variable effect makes control difficult, whereas the interaction concerns the combination's thrombotic risk.
How serious is the interaction between Amivantamab and Lazertinib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Give anticoagulant prophylaxis during the first months of therapy, preferably with a direct oral anticoagulant or low molecular weight heparin rather than a vitamin K antagonist. Monitor for signs of VTE.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
